Zacks Research Has Negative Outlook for BMY Q1 Earnings

Bristol-Myers Squibb (NYSE:BMY - Free Report) - Zacks Research cut their Q1 2027 earnings estimates for shares of Bristol-Myers Squibb in a report released on Tuesday, April 1st. Zacks Research analyst E. Bagri now expects that the biopharmaceutical company will earn $1.34 per share for the quarter, down from their prior estimate of $1.35. The consensus estimate for Bristol-Myers Squibb's current full-year earnings is $6.74 per share. Zacks Research also issued estimates for Bristol-Myers Squibb's FY2027 earnings at $6.05 EPS.

Other equities research analysts have also recently issued research reports about the stock. Wells Fargo & Company increased their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research report on Friday, February 7th. Cantor Fitzgerald increased their target price on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Citigroup boosted their price target on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Jefferies Financial Group upgraded Bristol-Myers Squibb from a "hold" rating to a "buy" rating and increased their price objective for the stock from $63.00 to $70.00 in a report on Monday, December 16th. Finally, Bank of America reiterated a "neutral" rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $57.86.

Remove Ads

Bristol-Myers Squibb Trading Down 4.3 %

Shares of NYSE:BMY traded down $2.50 during trading on Wednesday, reaching $55.32. 14,647,817 shares of the company traded hands, compared to its average volume of 12,762,583. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33. The business's fifty day moving average is $58.62 and its 200-day moving average is $56.58. The firm has a market capitalization of $112.56 billion, a price-to-earnings ratio of -12.52, a P/E/G ratio of 2.07 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, topping the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be paid a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.48%. The ex-dividend date of this dividend is Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is -56.11%.

Insider Activity

In related news, EVP Samit Hirawat purchased 1,823 shares of the business's stock in a transaction that occurred on Friday, February 14th. The shares were bought at an average price of $54.84 per share, for a total transaction of $99,973.32. Following the purchase, the executive vice president now directly owns 63,932 shares of the company's stock, valued at approximately $3,506,030.88. This represents a 2.94 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.09% of the company's stock.

Institutional Investors Weigh In On Bristol-Myers Squibb

Several hedge funds have recently added to or reduced their stakes in the stock. Moody National Bank Trust Division boosted its stake in Bristol-Myers Squibb by 2.8% in the 1st quarter. Moody National Bank Trust Division now owns 37,070 shares of the biopharmaceutical company's stock worth $2,261,000 after purchasing an additional 995 shares in the last quarter. Agate Pass Investment Management LLC bought a new position in shares of Bristol-Myers Squibb in the first quarter worth approximately $213,000. Legacy Private Trust Co. grew its holdings in shares of Bristol-Myers Squibb by 11.0% during the first quarter. Legacy Private Trust Co. now owns 10,819 shares of the biopharmaceutical company's stock valued at $660,000 after buying an additional 1,068 shares during the last quarter. Cadinha & Co. LLC bought a new stake in shares of Bristol-Myers Squibb during the first quarter valued at approximately $203,000. Finally, Versant Capital Management Inc raised its holdings in Bristol-Myers Squibb by 3.4% in the 1st quarter. Versant Capital Management Inc now owns 81,348 shares of the biopharmaceutical company's stock worth $4,961,000 after acquiring an additional 2,658 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.